Norway Dan Schneider discusses the continuing Norwegian identity of Photocure, despite its increasingly global footprint, the company’s strategy, and his background within the life sciences sector. We are a flagbearer for all Norwegian life sciences firms moving from development to commercialisation and a prime example of what the future could…
Norway John-Arne Røttingen, CEO of The Research Council of Norway shares his career journey from academia to industry, outlines his new role as Norway’s Global Health ambassador and gives his thoughts on Norway’s biotech and life sciences future. On a country by country basis, Norway has had the highest proportion…
Taiwan Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges Charles, could you start by introducing…
USA In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020, what it means for that Aducanumab, and the impact on next-generation AD treatments. November 6 could prove to be…
USA Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain political capital despite massive and proven flaws. Drug importation is a curious “zombie” proposal that never seems to die Donald Trump and Bernie Sanders have one…
USA Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded to the COVID-19 pandemic and the solutions that PhRMA is proposing to lower patient costs while protecting innovation and access. We know that our innovation and our collaboration…
Mexico COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has signed a deal with six Indian generics firms to establish a pharma hub for manufacturing and logistics. One of the leading pharma markets in Latin…
USA Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into rare diseases, product launch strategies, access and affordability issues, and talent attraction challenges. While it is true you can make great contributions in academia, I think you can make…
USA Brent Ragans of Ferring Pharmaceuticals US discusses the effects of the COVID-19 pandemic on the company’s operations, their footprint in reproductive health and Crohn’s Disease, virtual product launches and digitalisation, and the battle for talent in the competitive US market. US physicians have learned that, out of necessity, they…
Talent COVID-19 has necessitated enormous shifts in the way we live, work, and communicate with each other. Nowhere is this more apparent professionally than for those starting a new job. Here, we highlight four recent appointees to new roles in pharma companies across Europe and the USA and how they have…
France A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics biotech Novacyt’s remarkable rise, and a new job for former Ipsen boss Marc de Garidel. Sanofi aims for COVID-19…
USA Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a wide range of patient groups, increasing access and driving down costs in the process. 2020 has been an exceptionally turbulent year – especially for the…
See our Cookie Privacy Policy Here